Skip to main content
OpenTrials
Completed

NCT Number: NCT02387606

Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.

The purpose of this study is to evaluate the antiviral effect of repeated oral dosing of JNJ 53718678 compared to placebo in healthy adult participants infected through inoculation with respiratory syncytial virus (RSV)-A Memphis 37b virus.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Respiratory Syncytial Virus Infections Infections Mononegavirales Infections Paramyxoviridae Infections Pneumovirus Infections RNA Virus Infections Virus Diseases

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

London, United Kingdom

About this study

This is a randomized (study medication assigned to participants by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), placebo-controlled, single-center study of JNJ 53718678 in healthy adult participants. Study consists of 3 phases: Screening (Day -56 and Study Day -3 prior to the planned date of virus inoculation/challenge on Study Day 0), quarantine (includes challenge on Day -1 or -2 and treatment for 7 days), and follow-up (Day 15 and 28). Participants will be admitted to the quarantine unit on Study Day -1 or - 2 and will be inoculated (intranasal) with the RSV-A Memphis 37b virus on Study Day 0. Participants will be evaluated in 3 cohorts: Cohort 1 and Cohort 3 (participants will be dosed with JNJ-53718678 or placebo for 7 days) and Cohort 2 (for up to 7 days [Dosing Days 1-x] [x will be determined based on the results from Cohort 1]). Participants will be randomized and JNJ-53718678/placebo dosing will be started after RSV presence in nasal wash has been detected by polymerase chain reaction (PCR). After completion of Cohort 1, data will be reviewed (unblinded) and the antiviral activity, safety, pharmacokinetic, clinical symptom and mucus weight data will be evaluated, based on which Cohort 2 will be initiated. Participants' safety will be monitored throughout the study.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Female participants must be of non-childbearing potential: postmenopausal for at least 2 years or surgically sterile or otherwise incapable of becoming pregnant
  • Female participants, except for postmenopausal women, must have a negative serum pregnancy test at screening
  • Participants must agree to comply with contraceptive measures as mentioned in protocol
  • Participants must be sero-suitable for respiratory syncytial virus (RSV) within 57 days prior to inoculation
  • Participants must be non-smokers for at least one month prior to screening and participants must have a negative cotinine test at screening

Exclusion criteria

  • Participants with a past history of heart arrhythmias (extrasystoli, tachycardia at rest) or of risk factors for Torsade de Pointes syndrome
  • Participants with a history or evidence of abuse of alcohol, barbiturates, amphetamines, recreational or narcotic drug use within the past 3 months, which in the Investigator's opinion would compromise participant's safety and/or compliance with the study procedures
  • Participants with current human immunodeficiency virus type 1 (HIV-1) or HIV-2 infection at screening
  • Participants with current hepatitis A infection, or hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection (confirmed by HCV antibody) at screening
  • Participants with active acute respiratory infection at admission (Study Day -1 or -2)

Treatment and study plan

Placebo

Drug

Participants will receive placebo once daily.

JNJ-53718678

Drug

Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.

Primary outcomes

  1. Area Under the Viral Load-time Curve (VL AUC)

    Time frame: up to Follow-up (Day 28)

    VL AUC for RSV-A Memphis 37b will be determined by quantitative reverse transcriptase -polymerase chain reaction (qRT-PCR) assay of nasal wash. The VL AUC will be calculated based on the viral load values measured 2 times per day, starting with the last value prior to first dosing, and ending with the last available value before discharge.

Secondary outcomes

  1. Area Under the Viral Load-time Curve (VL AUC) Determined by Plaque Forming Unit (PFU) Assay

    Time frame: Baseline up to Follow-up (Day 28)

    VL AUC for RSV-A Memphis 37b will be determined by PFU assay of nasal wash.

  2. Viral Load Over Time

    Time frame: Baseline up to Follow-up (Day 28)

  3. Peak Viral Load

    Time frame: Baseline up to Follow-up (Day 28)

  4. Time To Peak Viral Load

    Time frame: Baseline up to Follow-up (Day 28)

    Time to peak viral load will be reported.

  5. Area Under the Viral Load-time Curve (VL AUC) From Time 0 to 24 Hours after First Dose

    Time frame: 24 hours after first dose

  6. Area Under the Viral Load-time Curve (VL AUC) From Time 0 to 48 Hours after First Dose

    Time frame: 48 hours after first dose

  7. Time to Non-detectability of Virus

    Time frame: Baseline up to Follow-up (Day 28)

    Time to non-detectability of virus from first administration of study drug will be assessed.

  8. Total Clinical Symptom Score

    Time frame: Admission (Day -1 or -2) up to Day 13

    Total clinical symptom score will be assessed using a composite of 10 self-reported symptoms on the Symptom Diary Card. The Investigator will review the participant's SDC entries on a daily basis after the administration of challenge virus inoculum. Total Clinical Symptom Score ranges from 0 (no symptoms) to 3 (not well).

  9. Time to Peak Symptom Score After Viral Inoculation

    Time frame: Admission (Day -1 or -2) up to Day 13

  10. Mucus Weight

    Time frame: Baseline up to Day 13

  11. Tissue Count

    Time frame: Baseline up to Day 13

  12. Sequence Analysis of the Rsv-A Memphis 37b Genome

    Time frame: Baseline and post-Baseline

  13. Forced Expiratory Volume in 1 Second (FEV1) Measured by Spirometry

    Time frame: Baseline up to Follow-up (Day 28)

    FEV1 is the amount of air that can be exhaled in one second. FEV1 will be measured by spirometry. A positive change from baseline in FEV1 indicates improvement in lung function.

  14. Forced Vital Capacity (FVC) Measured by Spirometry

    Time frame: Baseline up to Follow-up (Day 28)

    FVC is the total volume of air expired after a full inspiration.

  15. FEV1/FVC Ratio

    Time frame: Baseline up to Follow-up (Day 28)

Sponsors and collaborators

Lead sponsor

Janssen Sciences Ireland UC

Industry

Registry information

Official study title

A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Subjects

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Mar 13, 2015
Registry last updated
Oct 26, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.